Intestinal Motility Assays
Changes in intestinal motility are associated with disorders such as irritable bowel syndrome (IBS), crohn’s, ulcerative colitis, and diarrhea. Understanding how test compounds influence motility is critical for advancing drug discovery in gastrointestinal (GI) research.
Image: An example of healthy intestinal tissue used in our gut motility studies.
Our Organ Bath Model for Intestinal Motility Studies
Using an electrically stimulated organ bath model, we assess changes in intestinal motility in response to test compounds. This system allows us to measure smooth muscle contractility in isolated human intestinal tissue, providing physiologically relevant insights that are often missing from conventional in vitro models.
Advantages of Our Human Tissue-Based Approach
Current in vitro technologies for assessing intestinal function have limitations, including:
- Lack of a physiologically accurate epithelial structure
- Absence of stromal cells and paracrine signaling
- Abnormal functional characteristics
- Oversimplified and outdated methodologies
By leveraging intact human tissue, our model overcomes these challenges, delivering more predictive and translatable data for drug development.
Study Design & Data Output
- Reference compounds available: Galantamine and Meptazinol
- Testing conducted in duplicate at six concentrations
- Responses expressed as % change from baseline electrical field stimulation (EFS) response
Our advanced human tissue models provide a robust platform for evaluating the effects of novel therapeutics on intestinal motility, ensuring more accurate predictions of clinical outcomes.
This model uses electrically stimulated tissues to assess whether your test article affects GI motility compared with Galantamine.
This model uses electrically stimulated tissues to assess whether your test article affects small or large intestine motility.